

Resource Summary Report

Generated by [nidm-terms](#) on Aug 15, 2026

Recombinant Anti-PARP1 antibody [EPR18461]

RRID:AB_2861274

Type: Antibody

Proper Citation

Abcam Cat# ab191217, RRID:AB_2861274

Antibody Information

URL: http://antibodyregistry.org/AB_2861274

Proper Citation: Abcam Cat# ab191217, RRID:AB_2861274

Target Antigen: PARP1

Host Organism: rabbit

Clonality: recombinant

Comments: Applications: WB, IHC-P, ICC/IF

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: Recombinant Anti-PARP1 antibody [EPR18461]

Description: This recombinant targets PARP1

Target Organism: rat, mouse, human

Clone ID: EPR18461

Antibody ID: AB_2861274

Vendor: Abcam

Catalog Number: ab191217

Record Creation Time: 20250820T055217+0000

Record Last Update: 20250820T224057+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Recombinant Anti-PARP1 antibody [EPR18461].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Rivera M, et al. (2026) APOBEC3B enhances the efficacy of PARP inhibitors in elimination of ovarian cancer stem cell. Scientific reports, 16(1), 5194.

Wang Q, et al. (2026) FANCA-dependent FEN1 recruitment suppresses transcription-replication conflicts and PARPi sensitivity. Molecular cell.

Ke H, et al. (2026) Knockout of PARP2 in T cells leads to spontaneous colitis with distinct segmental characteristics in PARP1-deficient mice. Frontiers in immunology, 17, 1741798.

Zhou L, et al. (2025) Halting hepatocellular carcinoma: Identifying intercellular crosstalk in HBV-driven disease. Cell reports, 44(4), 115457.

Fu Z, et al. (2025) Empty Spiracles Homeobox 2 Transcription Factor Functions as a Tumor Suppressor in Renal Cell Carcinoma by Targeting CADM1. Molecular cancer research : MCR, 23(7), 597.

Arenillas C, et al. (2025) Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes. Cancer discovery, 15(5), 1037.

Mei B, et al. (2024) All-trans retinoic acid sensitizes epithelial ovarian cancer to PARP inhibition after exposure to cisplatin. Molecular cancer therapeutics.

Wu J, et al. (2023) A cell transmembrane peptide chimeric M(27-39)-HTPP targeted therapy for hepatocellular carcinoma. iScience, 26(5), 106766.

Yuan P, et al. (2022) Poly (ADP-ribose) polymerase 1-mediated defective mitophagy contributes to painful diabetic neuropathy in the db/db model. Journal of neurochemistry, 162(3), 276.